FibroGen, Inc. (0IL8.L)

1,1500 -0,0204 (-1,74%) In data: 03:09PM BST. Mercato aperto.

FibroGen, Inc.

409 Illinois Street
San Francisco, CA 94158
United States
415 978 1200
https://www.fibrogen.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 486

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Thane Wettig	CEO & Director	941,79k	N/D	1965
Mr. Juan Graham	Senior VP & CFO	892,49k	N/D	1977
Ms. Christine L. Chung	Senior Vice President of China Operations	915,36k	N/D	1968
Dr. Barry A. Berkowitz Ph.D.	Founder	N/D	N/D	N/D
Dr. John J. Hunter Ph.D.	Chief Scientific Officer	N/D	N/D	1963
David DeLucia	Vice President of Corporate FP&A and Investor Relations	N/D	N/D	N/D
Mr. Michael D. Lowenstein J.D., Ph.D.	Chief Legal Officer	N/D	N/D	N/D
Ms. Tricia Stewart	Chief People Officer	N/D	N/D	N/D
Mr. Kirk A. Christoffersen MBA	Chief Business Officer	N/D	N/D	1969
Dr. Rahul Rajan Kaushik Ph.D.	Senior Vice President of Pharmaceutical Development, Technical Operations & Manufacturing	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di FibroGen, Inc. al 29 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 2; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.